DY2 Stock Chart & Stats
CHF9.93
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF9.93
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF8.94 - CHF11.46
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
CHF1.75B
Enterprise ValueCHF4.20K
Total Cash (Recent Filing)CHF239.00M
Total Debt (Recent Filing)CHF2.31B
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Oct 29, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF11.35Price Target Upside14.27% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.23
Revenue Forecast (FY)CHF2.87B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow gives Dentsply Sirona internal funding for R&D, commercial investments and debt service. Although below prior peaks, ongoing cash generation provides resilience while the company works through its turnaround.
Recurring Consumables And Broad PortfolioRepeat-use consumables and coverage across multiple dental disciplines create recurring customer demand and reduce reliance on any single product. The installed equipment base can also support follow-on consumable, software and service revenue.
Product Innovation And Wellspect GrowthWellspect’s growth demonstrates that product launches and geographic expansion can generate traction despite broader weakness. Continued innovation and adoption may provide a durable growth platform as investments in R&D and commercial capabilities mature.
Bears Say
Persistent Revenue Decline And LossesMulti-year revenue contraction and continuing net losses indicate that the turnaround has not yet restored durable growth or profitability. Sustained weakness can limit reinvestment capacity and make improvement dependent on successful execution of the recovery plan.
Elevated LeverageHigher leverage reduces financial flexibility while earnings remain weak and returns on equity are negative. Debt obligations may constrain acquisitions, investment and shareholder returns, and increase the consequences of any prolonged operating underperformance.
Broad-Based Segment PressureWeakness across OIS, consumables, CAD/CAM and treatment centers suggests the pressure is broader than one isolated product line. This raises execution risk because recovery requires simultaneous improvement across regional demand, channels and product categories.
DENTSPLY SIRONA News
DY2 FAQ
What was DENTSPLY SIRONA Inc’s price range in the past 12 months?
DENTSPLY SIRONA Inc lowest stock price was CHF8.94 and its highest was CHF11.46 in the past 12 months.
What is DENTSPLY SIRONA Inc’s market cap?
DENTSPLY SIRONA Inc’s market cap is CHF1.75B.
When is DENTSPLY SIRONA Inc’s upcoming earnings report date?
DENTSPLY SIRONA Inc’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.
How were DENTSPLY SIRONA Inc’s earnings last quarter?
DENTSPLY SIRONA Inc released its earnings results on Aug 06, 2026. The company reported CHF0.418 earnings per share for the quarter, beating the consensus estimate of CHF0.28 by CHF0.138.
Is DENTSPLY SIRONA Inc overvalued?
According to Wall Street analysts DENTSPLY SIRONA Inc’s price is currently Undervalued.
Does DENTSPLY SIRONA Inc pay dividends?
DENTSPLY SIRONA Inc does not currently pay dividends.
What is DENTSPLY SIRONA Inc’s EPS estimate?
DENTSPLY SIRONA Inc’s EPS estimate is 0.26.
How many shares outstanding does DENTSPLY SIRONA Inc have?
Currently, no data Available
What happened to DENTSPLY SIRONA Inc’s price movement after its last earnings report?
DENTSPLY SIRONA Inc reported an EPS of CHF0.418 in its last earnings report, beating expectations of CHF0.28. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA Inc?
Currently, no hedge funds are holding shares in CH:DY2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF11.35 (14.27% Upside)
CHF11.35 (14.27% Upside)
Blogger Sentiment
Neutral
CH:DY2 Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth CHF414.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Company Description
DENTSPLY SIRONA Inc
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
DY2 Company Deck
DY2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.View all CH:DY2 earnings summariesDY2 Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
DY2 Stock 12 Month Forecast
Average Price Target
CHF11.35
▲(14.27% Upside)